MARKET

HRTX

HRTX

Heron Therapeutics Inc
NASDAQ
2.800
+0.210
+8.11%
Closed 19:07 04/23 EDT
OPEN
2.700
PREV CLOSE
2.590
HIGH
3.145
LOW
2.700
VOLUME
6.56M
TURNOVER
0
52 WEEK HIGH
3.220
52 WEEK LOW
0.5000
MARKET CAP
420.92M
P/E (TTM)
-3.4983
1D
5D
1M
3M
1Y
5Y
Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Nucor Corporation tumbled 6.5% to $179.20 on Tuesday. The company reported worse-than-expected quarterly financial results. Cyngn Inc. Shares jumped 100% after the company was chosen to supply John Deere with industrial automation. Pineapple Energy Inc. And Virgin Galactic Holdings, Inc. Were among the stocks moving in today's mid-day session.
Benzinga · 21h ago
HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday
Shares of HealthStream, Inc. Rose sharply on Tuesday following upbeat quarterly results. The Nasdaq Composite gained over 200 points in Tuesday's session. Hibbett shares climbed 18.4% to $85.85 after the company agreed to be acquired by JD Sports Fashion.
Benzinga · 1d ago
Heron Therapeutics Price Target Announced at $6.00/Share by Capital One
Dow Jones · 1d ago
Heron Therapeutics Initiated at Overweight by Capital One
Dow Jones · 1d ago
Capital One Initiates Coverage On Heron Therapeutics with Overweight Rating, Announces Price Target of $6
Benzinga · 1d ago
Weekly Report: what happened at HRTX last week (0415-0419)?
Weekly Report · 2d ago
Heron Therapeutics Inc: Other preliminary proxy statements
Press release · 4d ago
Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain
Seeking Alpha · 04/16 20:24
More
About HRTX
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.

Webull offers Heron Therapeutics Inc stock information, including NASDAQ: HRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HRTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HRTX stock methods without spending real money on the virtual paper trading platform.